Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MYRIAD GENETICS INCMYGN · Entity 5953 | EVP, Commercial | September 16, 2026 | September 17, 2026 |
| NEOGENOMICS INCNEO · Entity 2096 | President Advanced Diagnostics | February 23, 2024 | February 27, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MYRIAD GENETICS INC
Report date September 16, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 351,224 |
Reported balance
After 2026-09-16 transaction · row 1
1 source rowRow 1 · 2026-09-16 · Grant · Acquired 257,731 · Balance 351,224 F1: Consists of time-based restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of time-based restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date.
NEOGENOMICS INC
Report date February 23, 2024 · Filed February 27, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.45 · Expires 2034-02-23 | Direct | 42,344 |
Reported balance
After 2024-02-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2024-02-23 · Grant · Acquired 42,344 · Balance 42,344 F8: On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,329 |
Reported balance
After 2024-02-23 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2024-02-23 · Grant · Acquired 25,329 · Balance 25,329 F9: On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,204 |
Reported balance
Holding disclosure · report date 2024-02-23 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 21,204 F5: On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 25,330 |
Reported balance
After 2024-02-23 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2024-02-23 · Grant · Acquired 25,330 · Balance 25,330 F10: On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F6: Once vested, the shares of common stock are not subject to expiration. |
| Performance Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 21,204 |
Reported balance
Holding disclosure · report date 2024-02-23 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 21,204 F7: On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F6: Once vested, the shares of common stock are not subject to expiration. |
| Common StockSEC Table I · non-derivative | Direct | 128,921 |
Reported balance
Holding disclosure · report date 2024-02-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 128,921 F1: This balance includes 1,205 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.42 · Expires 2029-06-01 | Direct | 319,112 |
Reported balance
Holding disclosure · report date 2024-02-23 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 319,112 F2: On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date. F3: On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.65 · Expires 2030-05-11 | Direct | 39,683 |
Reported balance
Holding disclosure · report date 2024-02-23 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 39,683 F4: On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This balance includes 1,205 shares that were acquired pursuant to NeoGenomics' Employee Stock Purchase Plan (ESPP) since the date of the reporting person's last filing. The shares were acquired in transactions exempt from Section 16b-3.
F2: On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date.
F3: On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date.
F4: On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F5: On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F6: Once vested, the shares of common stock are not subject to expiration.
F7: On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company.
F8: On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date.
F9: On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date.
F10: On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2026 Filed Sep 17, 2026 20:34 UTC | MYRIAD GENETICS INC MYGN · Entity 5953 | GrantCommon Stock | 257,731 | $0.00 | $0.00 |
DisclosureSEC source: 0001931406-26-000007 · wk-form4_1789677266.xml · nonDerivative · entry 1 Sikri Vishal · CIK 0001931406 · EVP, Commercial 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 351,224 F1 · shares: Consists of time-based restricted stock units granted pursuant to the Issuer's 2026 Employee, Director and Consultant Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock and vests in three equal annual installments beginning on the first anniversary of the grant date. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 25,330 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 8 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,330 Underlying: Common Stock · 25,330 shares Expires not disclosed F10 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 25,330 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 37,996. 50% of the number of performance stock units that may vest is based on the achievements of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. 50% of the number of performance stock units that may vest is based on the achievement of certain revenue growth goals based on the achievement of the cumulative fiscal year revenue goal at the applicable measurement amounts, subject to continued service with the Company. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 25,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 7 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,329 Underlying: Common Stock · 25,329 shares Expires not disclosed F9 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 25,329 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:27 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 42,344 | $0.00 Strike: $16.45 | $0.00 |
DisclosureSEC source: 0001077183-24-000026 · wk-form4_1709069240.xml · derivative · entry 6 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,344 Underlying: Common Stock · 42,344 shares Expires 2034-02-23 F8 · derivative.exercise_date: On February 23, 2024, Mr. Sikri was granted 42,344 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 22:01 UTC | NEOGENOMICS INC NEO · Entity 2096 | Tax withholdingCommon Stock | 21,406 | $0.00 | $0.00 |
DisclosureSEC source: 0001931406-23-000002 · wk-form4_1685743307.xml · nonDerivative · entry 1 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,716 F1 · shares: Shares surrendered to NeoGenomics Inc. for retirement to satisfy the tax obligations in connection with the June 1, 2023 vesting of restricted stock. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantPerformance Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 5 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F7 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 21,204 performance stock units representing the number of shares that may vest at target performance. The maximum number of shares that may vest pursuant to the performance criteria is 31,806. The number of performance stock units that may vest is based on the achievement of certain share growth goals based on the weighted average price of the Company's common stock over the 20-day trailing trading period at the applicable measurement dates, subject to continued service with the Company. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantRestricted Stock Unit · Derivative | 21,204 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 4 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,204 Underlying: Common Stock · 21,204 shares Expires not disclosed F5 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 21,204 restricted stock units. These restricted stock units vest ratably over the first three anniversary dates of the grant date. F6 · derivative.expiration_date: Once vested, the shares of common stock are not subject to expiration. Read SEC document |
| May 11, 2023 Filed May 15, 2023 21:05 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 39,683 | $0.00 Strike: $19.65 | $0.00 |
DisclosureSEC source: 0001077183-23-000051 · wf-form4_168418474053523.xml · derivative · entry 3 Sikri Vishal · CIK 0001931406 · President Advanced Diagnostics 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,683 Underlying: Common Stock · 39,683 shares Expires 2030-05-11 F4 · derivative.exercise_date: On May 11, 2023, Mr. Sikri was granted 39,683 stock options. These options vest ratably over the first three anniversary dates of the grant date. Read SEC document |
| December 31, 2022 Filed Feb 1, 2023 22:37 UTC | NEOGENOMICS INC NEO · Entity 2096 | OtherCommon Stock | 225 | $7.04 | $1,584.00 |
DisclosureSEC source: 0001077183-23-000011 · wf-form5_167529103883294.xml · nonDerivative · entry 1 Sikri Vishal · CIK 0001931406 · President, Pharma Services 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,680 F1 · kind: These shares were acquired pursuant to NeoGenomics's Employee Stock Purchase Plan (ESPP) during the year ended December 31, 2022. The shares were acquired in transactions exempt from Section 16b-3. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantStock Option (Right to Buy) · Derivative | 319,112 | $0.00 Strike: $8.42 | $0.00 |
DisclosureSEC source: 0001077183-22-000091 · wf-form4_165420906324475.xml · derivative · entry 2 Sikri Vishal · CIK 0001931406 · President and CCO, Inivata 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 319,112 Underlying: Common Stock · 319,112 shares Expires 2029-06-01 F3 · derivative.exercise_date: On June 1, 2022, Mr. Sikri was granted 193,799 stock options. These options vest ratably over the first two anniversary dates of the grant date. F4 · derivative.exercise_date: On June 1, 2022, Mr. Sikri was granted 125,313 stock options. These options vest ratably over the first four anniversary dates of the grant date. Read SEC document |
| June 01, 2022 Filed Jun 2, 2022 22:31 UTC | NEOGENOMICS INC NEO · Entity 2096 | GrantCommon Stock | 148,455 | $0.00 | $0.00 |
DisclosureSEC source: 0001077183-22-000091 · wf-form4_165420906324475.xml · nonDerivative · entry 1 Sikri Vishal · CIK 0001931406 · President and CCO, Inivata 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,455 F1 · shares: On June 1, 2022, Mr. Sikri was granted 89,073 restricted stock awards. These awards vest ratably over the first two anniversary dates of the grant date. F2 · shares: On June 1, 2022, Mr. Sikri was granted 59,382 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.